Aurigene and Edity Forge Strategic Partnership in Cell Therapy

Aurigene Pharmaceutical Services Limited, a renowned CRDMO (Contract Research, Development, and Manufacturing Organization), has entered into a strategic partnership with Edity Therapeutics Limited, a biotechnology company specializing in cell therapy. As part of this collaboration, Aurigene will provide essential discovery services to bolster Edity's clinical development efforts.

This partnership follows a recent strategic investment by Dr. Reddy’s Laboratories Limited, Aurigene’s parent company, in Edity.

Edity is pioneering an innovative immune cell delivery platform that enables the precise delivery of therapeutic proteins directly into target cells. Their portfolio includes multiple product candidates spanning oncology, gene therapy, autoimmune disorders, and regenerative medicine. To expedite the clinical development of these cutting-edge technologies, Edity has sought out Aurigene's proven expertise in advanced therapy discovery services.

Aurigene, with its global reach and two decades of industry experience, supports pharmaceutical and biotech companies worldwide by providing accelerated development timelines and cost-effective manufacturing solutions for both biologics and small molecules. Their capabilities in biologics include a comprehensive range of discovery and development services for various therapeutic modalities such as antibodies, ADCs, cell therapeutics, and viral vectors.

Akhil Ravi, CEO of Aurigene, expressed enthusiasm about the partnership: "We are excited to collaborate with Edity and contribute to the development of groundbreaking technologies. Edity’s cellular reprogramming technology, which delivers therapeutic payloads specifically to target cells, introduces a new mechanism to CAR-T based cell therapeutics that could significantly enhance efficacy."

Michal Golan Mashiach, CEO of Edity, echoed this sentiment: “We are thrilled to partner with Aurigene's world-class team. Their extensive experience and diverse technology offerings will be instrumental in advancing our pipeline and aiding patients with severe diseases. This collaboration is a significant step towards our goal of developing best-in-class medicines.”